缬沙坦对肝硬化患者血清血管紧张素Ⅱ TGF-β1 影响.docVIP

缬沙坦对肝硬化患者血清血管紧张素Ⅱ TGF-β1 影响 　 作者：吴静黎 温帆渊 杨小云 李韶光 李秋梅 【摘要】 　　目的：探讨缬沙坦对肝硬化患者血清血管紧张素Ⅱ（AngⅡ）转化生长因子－β1 （TGF-β1 ）的影响及意义。方法：40例肝硬化患者被随机分为治疗组和对照组各20例，两组均给予常规治疗，治疗组在常规治疗基础上加用缬沙坦80mg/d，于治疗前及治疗6个月时采用ELISA法检测血清AngⅡ、TGF-β1。 结果:治疗前肝硬化患者血清AngⅡ（167.84±64.81vs 51.13±15.95pg/l）及TGFβ1 (181.12±32.63 vs31.46±10.39μg/l)水平均明显高于健康人，应用缬沙坦治疗后血清AngⅡ（168.67±69.03vs218.46±74.79 pg/l）较治疗前升高，而血清TGFβ1 (182.22±30.60vs121.77±13.84 μg/l)较治疗前下降,差异均有显著性。结论:血管紧张素ⅡⅠ型受体拮抗剂缬沙坦能降低血清TGFβ1 水平，具有一定的抗纤维化作用。 【关键词】 肝硬化 血管紧张素Ⅱ 转化生长因子－β1 缬沙坦 　　The Influence of Valsartan on Liver Cirrhosis in Serum Angiotension Ⅱ（AngⅡ） and Transforming Growth Factor-beta 1(TGF-β1 ) 　　　Abstract： Objective： To investigate the influence and clinical effect of valsartan on liver cirrhosis in serum AngⅡ and TGF-β1.Method： 40 liver cirrhsis patients were randomly divided into two groups : treatment group and control group,20 cases in each group ．The control group was treated with routine treatment，the treatment group，besides routine with treatment ,was added valsartan 80mg/day .Before treatment and after 6 months ELISA techniques were used to detect the levels of serum AngⅡ and TGFβ1 in 40 patients with liver cirrhosis .Result： Before treatment the levels of serum AngⅡ（167.84±64.81vs 51.13±15.95pg/l） and TGF-β1 (181.12±32.63 vs31.46±10.39μg/l) in liver cirrhosis were significantly higher than that in health peason .After treated with valsartan , serum AngⅡ（168.67±69.03vs218.46±74.79 pg/l）in after treatment 6 months was significantly higher than that before treatment , but TGF-β1 (182.22±30.60vs121.77±13.84μg/l)was lower significantly than that before.Conclusion： Angiotensin II type I receptor blocker valsartan can reduce the levels of serum TGFβ1, it can retard the progression of hepatic fibrosis. 　　Key words： Liver cirrhosis； AngiotensionⅡ； Transforming growth factor-beta 1； Valsartan 　　近年来研究表明,机体除有经典的肾素－血管紧张素系统(RAS)外，局部组织也存在RAS，肝脏也存在局部RAS［1,2］，RAS在各种器官的纤维化过程中发挥重要作用，血管紧张素－Ⅱ（AngⅡ）可促进转化生长因子－β1（TGF-β1）的产生，AngⅡ绝大部分生理功能必须通过与其Ⅰ型受体结合才能发挥。本研究探讨